TAK-242 prevents bleomycin-induced dermal and pulmonary fibrosis and mitigates increased collagen and α-SMA expression in cultured fibroblasts stimulated with fibronectin extra domain A isoform, a profibrotic treatment to simulate systemic sclerosis (78). Here, ACTA1 is linked to systemic sclerosis.